SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001493152-23-038044
Filing Date
2023-10-24
Accepted
2023-10-24 07:40:26
Documents
14
Period of Report
2023-10-24
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 form8-k.htm   iXBRL 8-K 35921
2 ex99-1.htm EX-99.1 17802
3 ex99-1_001.jpg GRAPHIC 20460
  Complete submission text file 0001493152-23-038044.txt   256969

Data Files

Seq Description Document Type Size
4 INLINE XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT evfm-20231024.xsd EX-101.SCH 3009
5 INLINE XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT evfm-20231024_lab.xml EX-101.LAB 34240
6 INLINE XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT evfm-20231024_pre.xml EX-101.PRE 22355
8 EXTRACTED XBRL INSTANCE DOCUMENT form8-k_htm.xml XML 3235
Mailing Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130
Business Address 12400 HIGH BLUFF DRIVE SUITE 600 SAN DIEGO CA 92130 (858) 550-1900
Evofem Biosciences, Inc. (Filer) CIK: 0001618835 (see all company filings)

IRS No.: 208527075 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36754 | Film No.: 231341177
SIC: 2834 Pharmaceutical Preparations